SEER INC CL A (DE) AJU IB Investment Co Ltd holding in Q1 2021 Form 13-F

Seer, Inc. provides the Proteograph Product Suite, which includes consumables, an automation instrument, and data analysis software designed for large-scale proteomic analysis. This suite is centered around proprietary engineered nanoparticle technology, which allows for comprehensive and rapid access to the proteome. The Proteograph facilitates a wide range of applications, such as basic and translational research, diagnostic development, and proteogenomics, by enabling the quantification of thousands of proteins and peptides from complex biological samples.

Seer operates within the global proteomics and genomics markets, targeting sectors like biobanks, biopharmaceutical companies, and academic institutions. The company generates revenue through the sale of its Proteograph systems, related consumables, and fee-for-service offerings via its Seer Technology Access Center (STAC) and Centers of Excellence (COEs). The Proteograph has been validated for use in various biological samples, enhancing its applicability across different research and diagnostic fields.

The company's operational structure includes direct sales teams in North America and the EU, with manufacturing operations based in Redwood City, California. Key factors impacting Seer's business performance include its ability to expand market access, maintain strategic partnerships, and continue technological innovation. Additionally, competition from established life sciences technology companies and emerging biotech firms influences its market position.